Beambalm Antifungal Foot Care Spray
NDC 87786-020
Product Information
Beambalm Antifungal Foot Care (tolnaftate 1% antifungal foot care) is a OTC MONOGRAPH DRUG-approved product labeled by Wenzhou Yuyuan Pharmaceutical Co., Ltd.. Tolnaftate is used to treat skin infections such as athlete's foot, jock itch, and ringworm. It is supplied as a spray for topical administration. This product entry covers the primary NDC 87786-020 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 87786-020?
What are the uses of this product?
What are Active Ingredients of this product?
- TOLNAFTATE 1 g/100mL - A synthetic antifungal agent.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- TOLNAFTATE (UNII: 06KB629TKV)
- TOLNAFTATE (UNII: 06KB629TKV) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- BENZOIC ACID (UNII: 8SKN0B0MIM)
- SOPHORA FLAVESCENS ROOT (UNII: IYR6K8KQ5K)
- PSEUDOLARIX AMABILIS BARK (UNII: 49G13A93VE)
- PHENYLEPHRINE HYDROCHLORIDE (UNII: 04JA59TNSJ)
- ALCOHOL (UNII: 3K9958V90M)
- EUPHORBIA HIRTA WHOLE (UNII: L13YF113GN)
- TEA TREE OIL (UNII: VIF565UC2G)
- PHELLODENDRON AMURENSE BARK (UNII: PBG27B754G)
* Please review the full disclaimer at the bottom of this page.
Patient Education
Tolnaftate
Tolnaftate stops the growth of fungi that cause skin infections, including athlete's foot, jock itch, and ringworm. This medication is sometimes prescribed for other uses; ask your doctor or pharmacist for more information.
[Learn More]
* Please review the full disclaimer at the bottom of this page.